Delivery of Exenatide and Insulin Using Mucoadhesive Intestinal Devices
A major disadvantage associated with current diabetes therapy is dependence on injectables for long-term disease management. In addition to insulin, incretin hormone replacement therapies including exenatide have added a new class of drugs for Type-2 diabetes. Although efficacious, patient compliance with current diabetic therapy is poor due to requirement of injections, inability to cross the intestinal epithelium and instability in the gastrointestinal tract. Here, we report the efficacy of a mucoadhesive device in providing therapeutic concentrations of insulin and exenatide via oral administration. Devices were prepared with a blend of FDA-approved polymers, carbopol, pectin and sodium carboxymethylcellulose, and were tested for drug carrying capability, in vitro release, Caco-2 permeability, and in vivo efficacy for insulin and exenatide. Results suggested that mucoadhesive devices successfully provided controlled release of FITC-insulin, released significant amounts of drug, while providing noteworthy enhancement of drug transport across Caco-2 monolayers without compromising monolayer integrity. In-vivo administration of the devices provided significant enhancement of drug absorption with 13- and 80-fold enhancement of relative bioavailability for insulin and exenatide compared to intestinal injections with significant increase in half-lives, thus resulting in prolonged blood glucose reduction. This study validates the efficacy of mucoadhesive devices in promoting oral peptide delivery to improve patient compliance and dose adherence.
KeywordsType-2 diabetes Oral delivery Peptides Absorption enhancement Exenatide Insulin
This research was funded by Otis Williams Fellowship from Santa Barbara Foundation (VG) and Enlight Biosciences. SM is a scientific advisor and shareholder of Entrega Inc.
- 3.American Diabetes Association. Standards of medical care in diabetes-2011. Diab. Care 34: S11–S61, 2011.Google Scholar
- 8.Cemeroglu, A. P., A. Can, A. T. Davis, O. Cemeroglu, L. Kleis, M. S. Daniel, J. Bustraan, and T. J. Koehler. Fear of needles in children with type 1 diabetes mellitus on multiple daily injections and continuous subcutaneous insulin infusion. Endocr. Pract. 21:46–53, 2015.CrossRefPubMedGoogle Scholar
- 12.Chuang, E. Y., G. T. Nguyen, F. Y. Su, K. J. Lin, C. T. Chen, F. L. Mi, T. C. Yen, J. H. Juang, and H. W. Sung. Combination therapy via oral co-administration of insulin- and exendin-4-loaded nanoparticles to treat type 2 diabetic rats undergoing OGTT. Biomaterials 34:7994–8001, 2013.CrossRefPubMedGoogle Scholar
- 29.Mansourpour, M., R. Mahjub, M. Amini, S. N. Ostad, E. S. Shamsa, M. Rafiee-Tehrani, and F. A. Dorkoosh. Development of acid-resistant alginate/trimethyl chitosan nanoparticles containing cationic beta-cyclodextrin polymers for insulin oral delivery. AAPS PharmSciTech 16:952–962, 2015.CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Nielsen, E. J., S. Yoshida, N. Kamei, R. Iwamae, S. Khafagy el, J. Olsen, U. L. Rahbek, B. L. Pedersen, K. Takayama, and M. Takeda-Morishita. In vivo proof of concept of oral insulin delivery based on a co-administration strategy with the cell-penetrating peptide penetratin. J. Control Release 189:19–24, 2014.CrossRefPubMedGoogle Scholar
- 45.Usansky J., A. Desai, and T.-L. D. PK functions for Microsoft Excel. 2003.Google Scholar
- 51.Yim, L. Belonephobia—a fear of needles. Aust. Fam. Phys. 35:623–624, 2006.Google Scholar
- 53.Zhu S., S. Chen, Y. Gao, F. Guo, F. Li, B. Xie, J. Zhou and H. Zhong. Enhanced oral bioavailability of insulin using PLGA nanoparticles co-modified with cell-penetrating peptides and Engrailed secretion peptide (Sec). Drug Deliv 1–12, 2015.Google Scholar